

University of Groningen

G-Protein Sensitivity of Ligand Binding to Human Dopamine D2 and D3 Receptors Expressed in Escherichia coli

Vanhouwe, Jurgen F.M.; Josson, Katty; Luyten, Walter H.M.L.; Driessen, Arnold J.; Leysen, Josée E.

Published in:
Journal of Pharmacology and Experimental Therapeutics

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2000

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Vanhouwe, J. F. M., Josson, K., Luyten, W. H. M. L., Driessen, A. J., & Leysen, J. E. (2000). G-Protein Sensitivity of Ligand Binding to Human Dopamine D2 and D3 Receptors Expressed in Escherichia coli: Clues for a Constrained D3 Receptor Structure. *Journal of Pharmacology and Experimental Therapeutics*, 295(1), 274-283.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

G-Protein Sensitivity of Ligand Binding to Human Dopamine D₂ and D₃ Receptors Expressed in *Escherichia coli*: Clues for a Constrained D₃ Receptor Structure¹

JURGEN F. M. VANHAUWE,² KATTY JOSSON, WALTER H. M. L. LUYTEN, ARNOLD J. DRIESSEN, and JOSÉE E. LEYSEN

Department of Biochemical Pharmacology (J.F.M.V., K.J., J.E.L.), and Department of Functional Genomics (W.H.M.L.L.), Janssen Research Foundation, Belgium; and Department of Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, The Netherlands (A.J.D.)

Accepted for publication July 3, 2000 This paper is available online at <http://www.jpet.org>

ABSTRACT

Human dopamine D₂ and D₃ receptors were expressed in Chinese hamster ovary (CHO) and *Escherichia coli* cells to compare their ligand binding properties in the presence or absence of G-proteins and to analyze their ability to interact with G_{i/o}-proteins. Binding affinities of agonists (dopamine, 7-OH-DPAT, PD128907, lisuride) and antagonists/inverse agonists (haloperidol, risperidone, domperidone, spiperone, raclopride, nemonapride), measured using [¹²⁵I]iodosulpride and [³H]7-OH-DPAT, were similar for hD₃ receptors in *E. coli* and CHO cell membranes. Both agonists and antagonists showed 2- to 25-fold lower binding affinities at hD₂ receptors in *E. coli* versus CHO cell membranes (measured with [³H]spiperone), but the rank order of potencies remained similar. Purported inverse agonists did not display higher affinities for G-protein-free receptors. In CHO membranes, GppNHp decreased high

affinity agonist ([³H]7-OH-DPAT) binding at hD₂ receptors but not at hD₃ receptors. Also, [³H]7-OH-DPAT (nanomolar concentration range) binding was undetectable at hD₂ but clearly measurable at hD₃ receptors in *E. coli* membranes. Addition of a G_{i/o}-protein mix to *E. coli* membranes increased high affinity [³H]7-OH-DPAT binding in a concentration-dependent manner at hD₂ and hD₃ receptors; this effect was reversed by addition of GppNHp. The potency of the G_{i/o}-protein mix to reconstitute high affinity binding was similar for hD₂ and hD₃ receptors. Thus, agonist binding to D₃ receptors is only slightly affected by G-protein uncoupling, pointing to a rigid receptor structure. Furthermore, we propose that the generally reported lower signaling capacity of D₃ receptors (versus D₂ receptors) is not due to its lower affinity for G-proteins but attributed to its lower capacity to activate these G-proteins.

Dopamine receptors belong to the superfamily of G-protein-coupled receptors. Five dopamine receptors have been found and classified into the D1-like family (D₁ and D₅ receptors) and the D2-like family (D₂, D₃, and D₄ receptors) (Missale et al., 1998). Receptor genes of the D1-like family do not contain introns, whereas members of the D2-like family possess multiple introns. For instance, two splice variants of the D₂ receptor have been found; the D_{2short} (D_{2S}) receptor, lacking a 29-amino acid insert in the third cytoplasmic loop, and the D_{2long} (D_{2L}) receptor (Monsma et al., 1989). Differ-

ences in G-protein coupling of these splice variants have been reported (Picetti et al., 1997), but the physiological relevance of these splice variants remains unclear.

Human dopamine D₂ and D₃ receptors have an overall amino acid sequence similarity of 52%, which increases to 78% if only transmembrane regions are considered (Giros et al., 1990). Most ligands that bind to hD₂ receptors also bind to hD₃ receptors and their rank order of potency is quite similar. In general, dopamine agonists have a higher affinity for hD₃ receptors, whereas antagonists have a slightly higher affinity for hD₂ receptors. The pharmacological properties of the hD₂ receptor splice variants are almost identical (Liu et al., 1992; Leysen et al., 1993; Schotte et al., 1996). Although both hD₂ and hD₃ receptors are thought to couple to G_{i/o} proteins, this is much less clear for the hD₃ than for the hD₂ receptor. Guanine nucleotide modulation of agonist binding

Received for publication April 12, 2000.

¹ This work was supported by a grant (project IWT 940232) from the IWT (Vlaams Instituut voor de Bevordering van het Wetenschappelijk-Technologisch Onderzoek in de Industrie).

² Present address: the laboratory of Dr. Heidi Hamm, Northwestern University, Institute of Neuroscience, Chicago, IL.

ABBREVIATIONS: CHO, Chinese hamster ovary; 7-OH-DPAT, (+)-7-(dipropylamino)-5,6,7,8-tetrahydro-2-naphthalenol; CHAPS, 3-[[3-cholamidopropyl]dimethylammonio]-1-propane sulfonate; DMSO, dimethyl sulfoxide; FCS, fetal calf serum; G-protein, heterotrimeric guanine nucleotide binding protein; GppNHp, guanylyl imidodiphosphate; hD₂, human dopamine D₂; hD₃, human dopamine D₃; pIC₅₀, -log IC₅₀ (concentration of the compound producing 50% inhibition of the specific binding of the radioactive ligand); pEC₅₀, -log EC₅₀ (concentration of the compound producing 50% effect).

at hD₂ receptors has been clearly demonstrated, whereas conflicting results have been obtained for hD₃ receptors (Sokoloff et al., 1992; Freedman et al., 1994; MacKenzie et al., 1994; Tang et al., 1994; Akunne et al., 1995; McAllister et al., 1995). In addition, coupling of hD₂ receptors to various pertussis-toxin-sensitive signaling pathways has been reported, whereas a total lack or a weak coupling to these pathways has been described for hD₃ receptors (MacKenzie et al., 1994; Tang et al., 1994; McAllister et al., 1995). Only recently, we succeeded in demonstrating clear activation of hD₃ receptors at different levels of the signal transduction cascade when expressed at high levels in Chinese hamster ovary (CHO) cells (Vanhouwe et al., 1999).

According to the allosteric ternary complex model (Lefkowitz et al., 1993; Samama et al., 1993), receptors, by themselves, can occur in an active and an inactive state. In the absence of agonist, a fraction of the receptor population can exist in an active state, leading to basal or constitutive activity. Agonist binding increases the population of active receptors. In contrast, binding of inverse agonists drives the receptor to the inactive state, diminishing the basal activity. It is not yet clear whether agonist binding recruits G-proteins to the activated receptor or that G-protein coupling promotes subsequent agonist binding. Probably, both processes play in concert (ternary complex formation). However, it is generally found that agonists bind with higher affinity to G-protein-coupled receptors than to uncoupled receptors, whereas neutral antagonists do not distinguish between G-protein-coupled and uncoupled receptors. Furthermore, it was suggested that inverse agonists have a higher affinity for uncoupled than for G-protein-coupled receptors (Costa et al., 1992). Inverse agonists have been identified for D₂ (Hall and Strange, 1997; Kozell and Neve, 1997; Vanhouwe et al., 2000) and D₃ receptors (Griffon et al., 1996; Malmberg et al., 1998), indicating that both receptors can have basal activity.

To demonstrate clearly the effect of G-protein receptor coupling on ligand binding, one would need the receptor in a G-protein-free environment. *Escherichia coli* cells, which do not contain G-proteins, provide a system for producing uncoupled receptors. Certain G-protein-coupled receptors have been successfully expressed in *E. coli* (Marullo et al., 1990; Freissmuth et al., 1991; Bertin et al., 1992; Grishammer et al., 1993; Munch et al., 1995).

In this study, we succeeded for the first time to express hD_{2S}, hD_{2L}, and hD₃ receptors in *E. coli*. To scrutinize the difference in G-protein-coupling properties of hD_{2S}, hD_{2L}, and hD₃ receptors, we compared the binding properties of agonists and antagonists for recombinant receptors expressed in *E. coli* versus CHO cells. Measurements on recombinant hD₂ and hD₃ receptors in *E. coli* membranes were carried out in the absence or presence of added G_{i/o}-proteins. Our study illustrates that agonist binding to hD₃ receptors is poorly sensitive to G-protein coupling, whereas hD₂ receptor high affinity agonist binding is highly dependent on G-proteins. Nevertheless, hD₃ and hD₂ receptors were found to have equal affinity for the G_{i/o}-protein mix. A constrained hD₃ receptor structure that retains a conformation of high affinity agonist binding in the uncoupled and G-protein state is hypothesized, along with a conformation that binds well, but poorly activates G-proteins.

Experimental Procedures

Bacterial Expression and Membrane Preparation. The cDNAs of hD_{2S}, hD_{2L}, and hD₃ receptors were cloned, and the sequence was verified by DNA sequencing (Schotte et al., 1996). For each receptor, the cDNA was ligated in the expression vector pMal-p so that it was in-frame with the maltose binding protein (MalE). All plasmid constructs were confirmed by DNA sequencing. The resulting plasmids coded for the MalE protein fused via a polylinker, containing a protease factor Xa cleavage site, to the receptor at the C terminus. Fusion and wild-type plasmids were transformed into competent *E. coli* TB1 cells [araΔ (lac proAB) rpsL (Φ80 lacΔM15) hsdR] by electroporation and plated on 2xYT plates containing 100 μg/ml ampicillin. A single colony was inoculated into 2 ml of 2xYT medium containing 100 μg/ml ampicillin. After 8 h of growth, the 2-ml starter culture was added to 500-ml 2xYT medium containing 100 μg/ml ampicillin and grown overnight in a shaking incubator (New Brunswick Scientific, Edison, NJ) at 300 rpm and 37°C. The optical density was determined, and the cells were harvested by centrifugation (2000g for 10 min at 4°C) and resuspended to an optical density of 1.5 in 2xYT, containing 100 μg/ml ampicillin and 0.5 mM isopropyl-β-D-thiogalactopyranoside. Cells were further incubated for 4 h at 25°C, harvested by centrifugation, and resuspended in ice-cold 50 mM Tris-HCl, pH 7.4, containing 20% sucrose and 1 freshly dissolved tablet of protease inhibitor cocktail (Complete) per 50 ml. In a first series of experiments on the pharmacological characterization of hD₃ receptors, *E. coli* cell suspensions were frozen as pellets and thawed before use. In subsequent studies on the characterization of D₂ receptors and addition of G-proteins to *E. coli* membranes, frozen droplets were prepared by freezing drops of the cell suspension in liquid nitrogen followed by storage at -70°C until use. After thawing of the droplets, the cell suspension was passed four times at 800 psi through a French press (Spectronic Instruments, Cheshire, England). The suspension was diluted in 50 mM Tris-HCl, pH 7.4, containing 10% glycerol. After a low spin centrifugation (1400g for 5 min at 4°C) for removal of intact cells, the supernatant was collected and centrifuged at 90,000g for 1 h at 4°C. The membrane pellet was suspended in 50 mM Tris-HCl, pH 7.4, containing 10% glycerol and used in radioligand binding experiments.

CHO Cell Culture and Membrane Preparation. CHO cells expressing the hD_{2S}, hD_{2L}, or D₃ receptors (Vanhouwe et al., 1999) were grown in Dulbecco's modified Eagle's medium supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin, and 10% fetal calf serum in a humidified atmosphere of 5% CO₂ at 37°C. Cells were subcultured at 80 to 90% confluence.

Cells were subcultured from 175-cm² tissue culture flasks to 145-cm² Petri dishes. At 90% confluence, 5 mM sodium butyrate was added to increase the receptor expression level and the cells were further incubated for 24 h (Palermo et al., 1991). The medium was removed, and the Petri dishes were washed once with 5 ml of ice-cold PBS and stored at -70°C. Cells on Petri dishes were thawed, and 5 ml of 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride was added per dish. The cells were harvested and homogenized with a dual homogenizer (motor-driven Teflon pestle and conical glass tube). The homogenate was centrifuged (10 min at 1000g at 4°C), and the resulting pellet was resuspended and centrifuged again (10 min at 1300g at 4°C). Both supernatants were pooled and centrifuged at 50,000g for 1 h at 4°C. The resulting pellet was resuspended in 50 mM Tris-HCl (pH 7.4), containing 10% glycerol and stored in aliquots at -70°C. The protein concentration in membrane preparations was measured with the Bradford protein assay using BSA as a calibration standard.

Radioligand Binding Assays. For radioligand binding experiments on hD₃R-*E. coli* cells, the cell suspension was thawed and washed twice in the incubation buffer for the ligand. For radioligand binding experiments on *E. coli* or CHO cell membranes, the mem-

branes were thawed and resuspended in the incubation buffer for the ligand.

[³H]7-OH-DPAT was used to measure agonist binding to hD₃, hD_{2S}, and hD_{2L} receptors. The incubation with [³H]7-OH-DPAT was performed for 30 min at 25°C in a total volume of 0.5 ml, containing 50 mM Tris-HCl, pH 7.4, 10 mM MgCl₂, and 1 mM EGTA (for hD_{2R}-*E. coli* membranes, the total incubation volume was 1 ml). [¹²⁵I]iodosulpride was used to measure antagonist binding to hD₃ receptors in *E. coli* cells and CHO cell membranes. The incubation with [¹²⁵I]iodosulpride was performed for 30 min at 25°C in a total volume of 0.25 ml, containing 50 mM Tris-HCl, pH 7.4, 120 mM NaCl, and 0.1% BSA. [³H]Spiperone was used to measure antagonist binding to hD_{2S} and hD_{2L} receptors in *E. coli* membranes and CHO cell membranes. The incubation with [³H]spiperone was performed for 30 min at 37°C in a total volume of 0.5 ml, containing 50 mM Tris-HCl, pH 7.4, and 120 mM NaCl (for hD_{2R}-*E. coli* membranes the total incubation volume was 1 ml). The amount of protein per incubation was 10 to 20 μg for *E. coli* membranes and cells and for hD_{2S}R-CHO cell membranes. For hD₃R-CHO and hD_{2L}R-CHO cell membranes 5 to 10 μg of protein was used. Nonspecific binding was estimated in the presence of 10 μM haloperidol. The reaction was terminated by filtration through Whatman GF/B filters, presoaked in 0.1% polyethyleneimine. Filters were rinsed twice with 5 ml of ice-cold incubation buffer. The filter-bound radioactivity was measured in a liquid scintillation spectrometer (Tricarb, Packard, Meriden, CT), using 3 ml of scintillation fluid. Specific binding was calculated as the difference between total binding and nonspecific binding. For ligand concentration binding isotherms, [³H]7-OH-DPAT was used at 10 to 12 concentrations in the range of 0.1 to 20 nM for CHO cell membranes and 0.1 to 10 nM for *E. coli* cell membranes (high concentrations of [³H]7-OH-DPAT resulted in high nonspecific binding at *E. coli* membranes), and [¹²⁵I]iodosulpride was used at 10 concentrations in the range of 0.1 to 3 nM and [³H]spiperone was used at 10 to 12 concentrations in the range of 0.01 to 1 nM.

Ligand concentration binding isotherms were fitted to a rectangular hyperbola by nonlinear regression analysis in which the apparent equilibrium dissociation constant (K_d) and the maximum number of binding sites (B_{max}) were free parameters. Computerized curve fitting was performed using the GraphPad Prism software.

In competition binding experiments at hD₃ receptors, serial dilutions of unlabeled compounds were incubated with [³H]7-OH-DPAT (2 nM) or [¹²⁵I]iodosulpride (0.4 nM) and CHO or *E. coli* membranes. In the case of hD_{2S} and hD_{2L} receptors, serial dilutions of unlabeled compounds (10–12 concentrations, range 0.1 mM to 0.1 nM) were incubated with [³H]spiperone (0.5 nM) and CHO or *E. coli* membranes. Competition curves were fit to a sigmoid by nonlinear regression analysis according to algorithms described by Oestreicher and Pinto (1987), in which the pIC₅₀ and the Hill coefficient were free parameters. Inhibition constants (K_i) were calculated according to Cheng and Prusoff (1973). Assays were run in duplicate in ligand concentration binding isotherms and in singlets in competition binding experiments and repeated in independent experiments (n numbers in tables and figures). Curves were calculated for individual experiments, and the mean of the derived parameters was calculated.

Reconstitution of High Affinity [³H]7-OH-DPAT Binding with G-Proteins. A commercially available bovine G_{i/o}-protein mix (Gα₁₁, Gα₁₂, Gα₁₃, Gα_o, Gβγ purified from bovine brain) was diluted in 50 mM Tris-HCl, pH 7.4, containing 10 mM MgCl₂, 1 mM EGTA, and 0.15% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS) and then 5-fold diluted and mixed with *E. coli* membrane suspension by vortexing. At this concentration of CHAPS, 90% of the binding is retained (results not shown). *E. coli* membranes (30–40 μg of protein/300 μl) were incubated in a total volume of 0.5 ml with serial dilutions of the G-protein mix and 0.75 nM or 2 nM [³H]7-OH-DPAT for hD₃ and hD_{2S} receptors, respectively. The assay buffer contained 50 mM Tris-HCl, pH 7.4, 10 mM MgCl₂, 1 mM

EGTA, and 0.03% CHAPS. After a 30-min incubation period at 25°C, the reaction was terminated by filtration and the amount of bound radioactivity was determined as described above. The concentration of the G_{i/o}-protein mix was calculated assuming an average molecular mass of 87,000 Da.

Materials. [³H]Spiperone (3.5 TBq/mmol), [¹²⁵I]iodosulpride (74.1 TBq/mmol), and [³H]7-OH-DPAT (5.5 TBq/mmol) were purchased from Amersham Pharmacia Biotech (Little Chalfont, UK). The *E. coli* strain (TB1) was from Stratagene (La Jolla, CA). The expression vector pMal-p was purchased from New England BioLabs (Leusden, Netherlands). The G_{i/o}-protein mix purified from bovine brain was obtained from Calbiochem (La Jolla, CA).

The 2xYT, Dulbecco's modified Eagle's medium, and fetal bovine serum were from Life Technologies (Gaithersburg, MD). The Bradford protein assay kit was from Bio-Rad (Richmond, CA). PD128907 and dopamine were purchased from Research Biochemicals International (Natick, MA). Raclopride and nemonapride were from Astra Arcus (Stockholm, Sweden) and Yamanouchi (Tokyo, Japan), respectively. TL99 was from ICN Pharmaceuticals (Costa Mesa, CA). Haloperidol, domperidone, risperidone, and spiperone are original products of Janssen Pharmaceutica (Beerse, Belgium). 7-OH-DPAT (racemic mixture) was synthesized in-house. Ampicillin, Complete protease inhibitor cocktail, CHAPS, isopropyl-β-D-thiogalactopyranoside, and 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride were purchased from Boehringer Mannheim (Mannheim, Germany). All other reagents were analytical grade from Merck (Haasrode, Belgium) or Sigma (St. Louis, MO). GF/B glass-fiber filters were from Whatman (Kent, UK). The scintillation fluid (Ultima Gold MV) was from Packard (Meriden, CT). The GraphPad Prism program was from GraphPad Software, Inc. (San Diego, CA). Dopamine, 7-OH-DPAT, and PD128907 were dissolved and diluted in assay buffer. Lisuride and TL99 were dissolved and diluted in ethanol. Haloperidol, spiperone, domperidone, risperidone, raclopride, and nemonapride were dissolved and diluted in dimethyl sulfoxide (DMSO). For compounds that were dissolved and diluted in DMSO or ethanol, a last dilution step of 20-fold in assay buffer was performed just before addition to the assay mixture in which the dilution was 10-fold. In control assays, ethanol or DMSO was added to a final concentration of 0.5%.

Results

Ligand Concentration Binding Isotherms at hD₃ Receptors. Ligand concentration binding isotherms on hD₃ receptors were measured with the partial agonist [³H]7-OH-DPAT and the antagonist [¹²⁵I]iodosulpride on *E. coli* cells and CHO cell membranes expressing the recombinant receptor (Vanhauwe et al., 1999). The ligand concentration binding curve of [¹²⁵I]iodosulpride on *E. coli* cells is shown in Fig. 1A. B_{max} and apparent K_d values obtained with hD₃R-*E. coli* cells and hD₃R-CHO cell membranes are shown in Table 1A. The affinity of [¹²⁵I]iodosulpride for hD₃ receptors expressed in *E. coli* or CHO cells was similar (K_d = 1.2–1.4 nM). Also, the agonist [³H]7-OH-DPAT bound with comparable affinity to hD₃R-*E. coli* cells and hD₃R-CHO cell membranes (K_d = 1.5 nM). The affinity of [³H]7-OH-DPAT for hD₃R-CHO cell membranes was not affected by addition of GppNHp. No binding could be detected in vector-transformed *E. coli* cells and CHO cell membranes with either radioligand.

Ligand Concentration Binding Isotherms for hD_{2S} and hD_{2L} Receptors. Ligand concentration binding isotherms on hD₂ receptors were measured with the partial agonist [³H]7-OH-DPAT and the antagonist [³H]spiperone. To improve the signal-to-noise ratio, membranes were prepared from *E. coli* cells expressing hD_{2S} or hD_{2L} receptors.




Fig. 1. Antagonist radioligand binding isotherms using [¹²⁵I]iodosulpride at hD₃-*E. coli* cells (A) and [³H]spiperone at hD_{2S}-*E. coli* (B) or hD_{2L}-*E. coli* (C) cell membranes. Experiments are performed as described under *Experimental Procedures*. Representative curves are shown in which each point was determined in duplicate. Mean K_d and B_{max} values of three to six experiments are shown in Table 1.

The ligand concentration binding curves of [³H]spiperone on hD_{2S}R- and hD_{2L}R-*E. coli* membranes are shown in Fig. 1, B and C, respectively. B_{max} and apparent K_d values are listed in Table 1B. The antagonist [³H]spiperone bound with a similar affinity to hD_{2S} and hD_{2L} receptors in *E. coli* than in CHO cell membranes (Student's *t* test, $P > .05$; $K_d = 0.1$ – 0.2 nM). [³H]7-OH-DPAT binding was undetectable in hD_{2S}R-*E. coli* or hD_{2L}R-*E. coli* cell membranes within the tested concentration range (0.1–10 nM). In contrast, [³H]7-OH-DPAT bound to hD_{2S}R- and hD_{2L}R-CHO cell membranes; its affinity was similar for either splice variant ($K_d = 2.3$ – 2.9 nM). Addition of GppNHp significantly decreased by nearly 4-fold the affinity of [³H]7-OH-DPAT for hD_{2S} (Student's *t* test, $P < .005$) and hD_{2L} (Student's *t* test, $P < .05$) receptors in CHO cell membranes.

Inhibition Binding Experiments at hD₃ Receptors.

The agonists dopamine, 7-OH-DPAT, PD128907, TL99, and lisuride and the presumed antagonists haloperidol, spiperone, domperidone, risperidone, raclopride, and nemonapride were tested for their potency to inhibit [¹²⁵I]iodosulpride and [³H]7-OH-DPAT binding to hD₃ receptors. The pIC_{50} and K_i values are listed in Table 2. In general, the apparent binding affinities of the antagonists for hD₃ receptors expressed in *E. coli* versus CHO cells were similar when using [¹²⁵I]iodosulpride or [³H]7-OH-DPAT. The apparent affinities of agonists were comparable for hD₃ receptors expressed in *E. coli* or CHO cells, when tested with [¹²⁵I]iodosulpride. When [³H]7-OH-DPAT was used, dopamine and 7-OH-DPAT were significantly (5–7-fold) less potent at *E. coli* than at CHO cell membranes (paired Student's *t* test, $P < .05$); no significant

decrease in potency could be found for PD128907, TL99, and lisuride in *E. coli* cells (paired Student's *t* test, $P > .05$). The rank order of potencies of agonists and antagonists was quite similar in hD₃R-*E. coli* and hD₃R-CHO cell membranes. In hD₃R-*E. coli* cells and CHO membranes, raclopride and nemonapride showed lower apparent binding affinities with [³H]7-OH-DPAT than with [¹²⁵I]iodosulpride. It should be noted that both compounds are benzamides like [¹²⁵I]iodosulpride; close structural similarities between nonlabeled and labeled ligands often leads to more effective inhibition.

Inhibition Binding Experiments at hD_{2S} and hD_{2L} Receptors. The same series of agonists and antagonists were tested for their potency to inhibit [³H]spiperone binding; pIC_{50} and K_i values are listed in Table 3. The rank order of antagonist potencies was similar for hD_{2S} and hD_{2L} receptors when expressed in *E. coli* or CHO cell membranes. The apparent binding affinities of antagonists for hD_{2L} receptors in *E. coli* membranes were two to five times lower than those in CHO cell membranes. Some compounds showed higher differences with the hD_{2S} receptor. Dopamine and 7-OH-DPAT were about 10 to 20 times less potent in *E. coli* membranes than in CHO cell membranes; PD128907 and lisuride were only three times less potent at hD₂-*E. coli* than at hD₂-CHO cell membranes. In CHO cell membranes, the potencies of compounds at hD_{2S} and hD_{2L} receptors were virtually similar. This was also the case for these splice variants when expressed in *E. coli* (except for raclopride).

Reconstitution of G-Protein Interaction with hD_{2S} and hD₃ Receptors in *E. coli*. In a first series of experiments (see Fig. 2), radioligand binding isotherms were deter-

TABLE 1

Binding affinities (K_d values in nM) derived from radioligand concentration binding isotherms with [¹²⁵I]iodosulpride (25°C), [³H]7-OH-DPAT (25°C), or [³H]spiperone (37°C) on hD₃ (A) or hD_{25L} (B) receptors expressed in *E. coli* and CHO cell membranes. The assay conditions for each radioligand are described under *Experimental Procedures*. Each value represents the mean of *n* experiments ± S.D. (*n* numbers between brackets), in which each point was determined in duplicate. Nonspecific binding was determined in the presence of 10 μM haloperidol. Significant differences are indicated in superscript and explained below the table.

Compound	Radioligand					
	hD ₃ - <i>E. coli</i>			hD ₃ -CHO		
	K_d	B_{max}	<i>n</i>	K_d	B_{max}	<i>n</i>
A)	[¹²⁵ I]iodosulpride	1.2 ± 0.1	3	1.4 ± 0.1	$5,100 \pm 1,500$	6
	[³ H]7-OH-DPAT	1.5 ± 0.3	7	1.5 ± 0.4	$4,800 \pm 1,800$	6
	[³ H]7-OH-DPAT + GppNHp	N.D.		1.5 ± 0.6	$5,600 \pm 1,700$	6
Radioligand						
B)	[³ H]spiperone	0.21 ± 0.02	5	0.14 ± 0.03	$13,800 \pm 2,500$	3
	[³ H]7-OH-DPAT	N.B.D.		2.3 ± 0.4	$5,000 \pm 1,200$	3
	[³ H]7-OH-DPAT + GppNHp	N.D.		8.2 ± 1.9^a	$1,200 \pm 100$	3
Radioligand						
Compound	hD _{25S} - <i>E. coli</i>			hD _{25S} -CHO		
	K_d	B_{max}	<i>n</i>	K_d	B_{max}	<i>n</i>
	nM	fmoI/mg protein		nM	fmoI/mg protein	
A)	[³ H]spiperone	$1,000 \pm 200$	3	0.19 ± 0.05	250 ± 40	4
	[³ H]7-OH-DPAT	N.B.D.		N.B.D.	N.B.D.	
	[³ H]7-OH-DPAT + GppNHp	N.D.		N.D.	N.D.	
Radioligand						
Compound	hD _{21L} - <i>E. coli</i>			hD _{21L} -CHO		
	K_d	B_{max}	<i>n</i>	K_d	B_{max}	<i>n</i>
	nM	fmoI/mg protein		nM	fmoI/mg protein	
B)	[³ H]spiperone	$1,000 \pm 200$	3	0.19 ± 0.05	250 ± 40	4
	[³ H]7-OH-DPAT	N.B.D.		N.B.D.	N.B.D.	
	[³ H]7-OH-DPAT + GppNHp	N.D.		N.D.	N.D.	

N.D., not determined; N.B.D., no binding detectable.

^a The affinity of [³H]7-OH-DPAT was significantly different from measurements without 100 μM GppNHp (paired Student's *t* test, *P* < .05).

TABLE 2

Binding affinities (pIC₅₀ mean ± S.D. and apparent K_i value, *n*) of agonists and antagonists at hD₃ receptors in *E. coli* cells and CHO cell membranes, derived from competition binding experiments using 0.4 nM [¹²⁵I]iodosulpride or 2 nM [³H]7-OH-DPAT at 25°C. Significant differences are indicated in superscript and explained below the table.

	[¹²⁵ I]Iodosulpride						[³ H]7-OH-DPAT					
	CHO			<i>E. coli</i>			CHO			<i>E. coli</i>		
	pIC ₅₀	K _i	<i>n</i>	pIC ₅₀	K _i	<i>n</i>	pIC ₅₀	K _i	<i>n</i>	pIC ₅₀	K _i	<i>n</i>
	-logM	nM		-logM	nM		-logM	nM		-logM	nM	
Agonists												
Dopamine	6.65 ± 0.20	170	6	6.53 ± 0.25	220	3	7.54 ± 0.06	10.7	3	6.80 ± 0.23	70.7 ^a	6
TL99	7.90 ± 0.02	9.8	3	7.98 ± 0.22	7.9	6	8.78 ± 0.09	0.63	3	8.67 ± 0.22	1.1	4
PD128907	8.04 ± 0.02	7.1	4	7.83 ± 0.11	11.1	3	7.94 ± 0.09	4.3	4	7.48 ± 0.35	14.8	3
7OH-DPAT	8.28 ± 0.19	4.1	4	8.15 ± 0.24	5.3	5	8.38 ± 0.10	1.6	3	7.79 ± 0.26	7.2 ^a	6
Lisuride	8.98 ± 0.27	0.81	4	9.45 ± 0.26	0.27	5	9.45 ± 0.11	0.13	5	9.67 ± 0.24	0.1	3
Antagonists												
Haloperidol	7.60 ± 0.19	19.4	4	7.30 ± 0.30	37.2	5	8.02 ± 0.20	3.6	4	7.21 ± 0.32	27.7	6
Domperidone	7.60 ± 0.20	19.4	3	7.51 ± 0.20	23.3	4	7.49 ± 0.18	12.1	4	7.18 ± 0.28	29.1	5
Risperidone	7.86 ± 0.29	10.9	6	8.01 ± 0.22	7.4	5	7.70 ± 0.16	7.4	3	7.68 ± 0.35	9.3	4
Raclopride	8.45 ± 0.09	2.8 ^b	5	8.51 ± 0.18	2.3 ^b	4	6.84 ± 0.25	53	5	6.49 ± 0.26	150	6
Spiperone	8.90 ± 0.07	0.98	5	8.73 ± 0.32	1.4	6	9.07 ± 0.18	0.32	5	8.61 ± 0.23	1.1	6
Nemonapride	9.31 ± 0.18	0.38 ^b	5	9.57 ± 0.29	0.2 ^b	4	8.50 ± 0.29	1.2	4	8.56 ± 0.15	1.2	5

^a The affinity of the compound for hD₃ receptors was significantly lower in *E. coli* than in CHO membranes (*P* < .05).

^b The affinity of the compound was significantly lower when tested with [³H]7-OH-DPAT (versus [¹²⁵I]iodosulpride) (*P* < .05).

TABLE 3

Binding affinities (pIC₅₀ mean ± S.D. and apparent K_i value, *n*) of agonists and antagonists at hD_{2S} and hD_{2L} receptors in *E. coli* membranes and CHO cell membranes, derived from competition binding experiments using 0.5 nM [³H]spiperone

	hD _{2S} Receptor						hD _{2L} Receptor					
	CHO			<i>E. coli</i>			CHO			<i>E. coli</i>		
	pIC ₅₀	K _i	<i>n</i>	pIC ₅₀	K _i	<i>n</i>	pIC ₅₀	K _i	<i>n</i>	pIC ₅₀	K _i	<i>n</i>
	-logM	nM		-logM	nM		-logM	nM		-logM	nM	
Agonists												
PD128907	4.59 ± 0.13	3900	3	4.39 ± 0.05	11600	3	4.46 ± 0.24	6000	3	4.30 ± 0.13	7600	3
7OH-DPAT	5.19 ± 0.22	1000	3	4.50 ± 0.15	9100 ^a	3	5.14 ± 0.03	900	3	4.20 ± 0.25	18000 ^a	3
Dopamine	5.60 ± 0.19	400	5	4.46 ± 0.25	9800 ^a	6	5.58 ± 0.18	400	5	4.60 ± 0.18	7200 ^a	5
Lisuride	7.96 ± 0.26	1.7	3	7.69 ± 0.24	5.8	3	8.11 ± 0.20	1.4	3	7.81 ± 0.23	4.4	3
Antagonists												
Raclopride	7.55 ± 0.28	4.4	4	6.41 ± 0.08	110 ^a	3	7.49 ± 0.12	4.9	4	6.22 ± 0.18	170 ^a	3
Risperidone	7.87 ± 0.16	2.3	3	7.53 ± 0.16	8.4	4	7.76 ± 0.16	2.7	4	7.47 ± 0.23	9.8	4
Nemonapride	8.36 ± 0.23	0.67	3	8.09 ± 0.29	1.3	4	8.44 ± 0.23	0.55	4	8.28 ± 0.29	0.8	4
Domperidone	8.57 ± 0.20	0.41	3	7.74 ± 0.19	5.2 ^a	4	8.23 ± 0.30	1	4	7.94 ± 0.13	3.3	4
Haloperidol	8.58 ± 0.20	0.41	4	7.60 ± 0.14	7.2 ^a	4	8.42 ± 0.11	0.58	4	7.96 ± 0.22	3.2 ^a	4
Spiperone	9.07 ± 0.05	0.13	3	9.01 ± 0.10	0.28	4	9.13 ± 0.14	0.1	4	9.05 ± 0.26	0.26	3

^a The affinity of the compound for hD_{2S/L} receptors was significantly lower in *E. coli* than in CHO membranes (*P* < .05).

mined with [³H]7-OH-DPAT using a fixed concentration (±2.3 nM) of the G-protein mix, which corresponds to a G-protein/receptor ratio as indicated in Fig. 3. To compare the agonist binding properties of hD₂ and hD₃ receptors, we have prepared membranes from *E. coli* cells and incubated them with the G-protein mix. The apparent affinity of [³H]7-OH-DPAT for hD₃ receptors in prepared membranes was virtually equal to that in hD₃R-*E. coli* cells, indicating that preparation of the membranes does not alter the binding properties of the receptor. [³H]7-OH-DPAT had an apparent binding affinity of 1.7 ± 0.2 nM (*n* = 4) for untreated (*B*_{max} = 2000 ± 300 fmol/mg of protein) and 1.1 ± 0.2 nM (*n* = 4) for G-protein-treated hD₃R-*E. coli* membranes (*B*_{max} = 2200 ± 300 fmol/mg of protein); addition of GppNHp along with the G-protein mix, resulted in an apparent binding affinity of 2.0 ± 0.3 nM (*n* = 4) (*B*_{max} = 2200 ± 200 fmol/mg of protein). As mentioned before, [³H]7-OH-DPAT binding at hD₂R-*E. coli* membranes could not be determined in the absence of G-proteins. However, when the G-protein mix was added to the membranes, [³H]7-OH-DPAT binding was

clearly detectable at hD_{2S}R-*E. coli* membranes (see Fig. 2) with an apparent binding affinity of 3.5 ± 0.1 nM (*n* = 2) (*B*_{max} = 160 ± 30 fmol/mg of protein); addition of GppNHp thereupon abolished [³H]7-OH-DPAT binding. At hD_{2L}R-*E. coli* membranes, [³H]7-OH-DPAT binding became apparent on addition of G-proteins, but the signal-to-noise ratio was too low for further characterization.

To determine the affinity of the G-protein mixture for hD_{2S} and hD₃ receptors, we added increasing amounts of the G-protein mixture to hD_{2S}R- or hD₃R-*E. coli* membranes and measured the increase in [³H]7-OH-DPAT binding, which was used at a concentration slightly lower than its determined apparent binding affinity in CHO cell membranes (i.e., 0.75 nM for hD₃ receptors and 2 nM for hD_{2S} receptors). Addition of G_{v10}-proteins increased [³H]7-OH-DPAT binding to hD_{2S}R and hD₃R-*E. coli* membranes in a concentration-dependent way (Fig. 3). The slopes of these curves were near unity. Derived pEC₅₀ values were 8.35 ± 0.06 (*n* = 4) for hD₃R-*E. coli* and 8.12 ± 0.06 (*n* = 4) for hD_{2S}R-*E. coli*. Apparently, the affinity of the G_{v10}-protein mix for both re-




Fig. 2. Radioligand binding isotherms using [^3H]7-OH-DPAT in the absence or presence of a $G_{i/o}$ -protein mix (2.3 nM) at hD_3 -*E. coli* membranes (A) and in the presence of a $G_{i/o}$ -protein mix (2.3 nM) at hD_{2S} -*E. coli* membranes (B). No specific [^3H]7-OH-DPAT binding to hD_{2S} -*E. coli* membranes could be detected in the absence of G-proteins. Experiments are performed as described under *Experimental Procedures*. Representative curves are shown in which each point was determined in duplicate. [^3H]7-OH-DPAT had an apparent binding affinity of 1.7 ± 0.2 nM ($n = 4$) for untreated ($B_{\max} = 2000 \pm 300$ fmol/mg of protein) and 1.1 ± 0.2 nM ($n = 4$) for G-protein-treated hD_3 -*E. coli* membranes ($B_{\max} = 2200 \pm 300$ fmol/mg of protein). [^3H]7-OH-DPAT had an apparent binding affinity of 3.5 ± 0.1 nM ($n = 2$) ($B_{\max} = 160 \pm 30$ fmol/mg of protein) for G-protein-treated hD_{2S} -*E. coli* membranes.

ceptors was quite similar for hD_3 than for hD_{2S} receptors (Student's *t* test, $P < .05$). Indeed, assuming a bimolecular interaction between the receptor and the heterotrimeric G-protein, we estimated apparent dissociation binding constants of 1.4×10^{-7} M in hD_3 -*E. coli* membranes and 9.4×10^{-8} M in hD_{2S} -*E. coli* membranes (for details of calculation see Fig. 3). Addition of the $G_{i/o}$ -protein mix to hD_{2S} -*E. coli* or hD_3 -*E. coli* membranes had no effect on antagonist binding (results not shown). At the highest concentration of the $G_{i/o}$ -protein mix, we estimated a G-protein/receptor ratio of 260 for hD_3 and of 780 for hD_{2S} receptors.

Discussion

We have used an *E. coli* and CHO expression system to investigate the ligand binding properties of hD_{2S} , hD_{2L} , and hD_3 receptors in the absence or presence of G-proteins, respectively. The goal was to obtain information on their receptor-G-protein interaction.

Successful Expression of hD_{2S} , hD_{2L} , and hD_3 Receptors in *E. coli*. We have demonstrated expression of hD_{2S} , hD_{2L} , and hD_3 receptors in *E. coli* membranes. The antagonist [^{125}I]iodosulpride and partial agonist [^3H]7-OH-DPAT bound with similar affinity to hD_3 receptors expressed in *E.*

coli and CHO cells (Table 1). In general, the apparent binding affinities and the rank order of potency of the antagonists and agonists tested were similar in hD_3 -*E. coli* cells and hD_3 -CHO cell membranes (Table 2). [^3H]Spiperone bound to hD_{2S} -*E. coli* and hD_{2L} -*E. coli* cell membranes with an apparent affinity comparable with hD_{2S} -CHO and hD_{2L} -CHO cell membranes (Table 1). The tested antagonists revealed apparent affinities at hD_{2S} -*E. coli* and hD_{2L} -*E. coli* membranes that were lower than their apparent affinities in hD_{2S} -CHO and hD_{2L} -CHO cell membranes, but the rank order of potency was similar, suggesting successful expression (Table 3). The lower apparent affinities of the ligands at hD_2 receptors in *E. coli* membranes may be attributed to sticking of the compounds and/or [^3H]spiperone (see Fig. 1, B and C: high nonspecific binding of [^3H]spiperone) to *E. coli* membranes. Alternatively, it may be attributed to the different composition of bacterial membranes; lower affinities of antagonists have also been observed for dopamine D_2 receptors expressed in *Saccharomyces cerevisiae* (Sander et al., 1994). Also, the different protein amount and assay volume in the binding assays for hD_2 -*E. coli* and -CHO membranes may lead to the lower apparent affinities of the compounds in *E. coli* membranes versus CHO membranes. Inhibition bind-




Fig. 3. Reconstitution of high affinity [³H]7-OH-DPAT binding at hD_{2S} and hD₃ receptors in *E. coli* membranes using a G_{i/o}-protein mix. Experiments are performed as described under *Experimental Procedures*. Curves represent the mean of four experiments \pm S.D. Derived pEC₅₀ values are 8.35 ± 0.06 for hD₃R-*E. coli* and 8.12 ± 0.06 for hD_{2S}R-*E. coli*. The same amount of protein (35 μ g) and incubation volume (0.5 ml) was used for hD_{2S}R-*E. coli* and hD₃R-*E. coli* membranes. The inset represents the increase of total bound [³H]7-OH-DPAT as a function of the ratio of G-protein/receptor. The arrows indicate the ratio G-protein/receptor that corresponds to what was used for generating the [³H]7-OH-DPAT saturation binding isotherms (see Fig. 2). Binding equilibrium constants were calculated assuming expression levels (B_{max}) of 2000 fmol/mg for hD₃ receptors and 1000 fmol/mg for hD_{2S} receptors and with the equation: $K = (B_{max} - [D_xR \cdot G])[G]/[D_xR \cdot G]$ in which $[D_xR \cdot G]$ is the concentration of the high affinity dopamine receptor-G-protein complex (difference between binding in untreated and G-protein-mixed membranes) and $[G]$ is the concentration of the exogenously added G-protein mix. K_d values were calculated using the estimated concentrations of the reaction components at the level of the pEC₅₀ values of the G-protein mix. We found for the hD₃R-G_{i/o}-protein an apparent K_d of 1.4×10^{-7} M and for the hD_{2S}R-G_{i/o}-protein an apparent K_d of 9.4×10^{-8} M.

ing constants using [³H]7-OH-DPAT in membranes of hD_{2S}R- or hD_{2L}R-expressing *E. coli* could not be determined due to the absence of radioligand binding at nanomolar concentration. In CHO and *E. coli* cell membranes, compounds had similar affinities for hD_{2S} and hD_{2L} receptors, respectively. This confirms previous findings and expands the idea of similar binding properties of these splice variants also to the G-protein-free environment in *E. coli* membranes (Schotte et al., 1996).

G-Protein Uncoupling Decreases High Affinity Agonist Binding at hD₂ Receptors. GppNHp treatment significantly decreased the affinity of [³H]7-OH-DPAT at hD_{2S}R-CHO and hD_{2L}R-CHO cell membranes (Table 1). Moreover, the lack of [³H]7-OH-DPAT binding at nanomolar concentration in hD_{2S}R-*E. coli* and hD_{2L}R-*E. coli* membranes indicates that hD₂ receptors have a low affinity for [³H]7-OH-DPAT in the total absence of G-proteins. Probably, G-proteins in CHO membranes cannot be fully dissociated from their receptor by GppNHp leading to an intermediate ("low") affinity for agonists. It was observed that [³H]7-OH-DPAT bound to hD_{2S}R-*E. coli* membranes in the presence of a G_{i/o}-protein mix with an affinity similar to what was found in hD_{2S}R-CHO cell membranes, indicating proper folding of the

receptor and reconstitution of the high affinity state. This reconstitution was reversible, because GppNHp treatment abolished [³H]7-OH-DPAT binding. Furthermore, we found significantly lower potencies (10–20-fold lower) of dopamine and 7-OH-DPAT for inhibition of [³H]spiperone binding to hD_{2S}R- and hD_{2L}R-*E. coli* membranes (Table 3), indicating again that high affinity agonist binding to D₂ receptors requires the presence of G-proteins.

G-Protein-Coupled and Uncoupled States of hD₃ Receptors Are Similar. It is generally assumed that D₃ receptors poorly couple to G-proteins or that the investigated cell systems do not possess the suitable G-proteins to explain a small (or no) shift in high affinity agonist binding on GTP γ S treatment. The latter assumption is further substantiated by studies reporting the inability of D₃ receptors to regulate effector systems (Freedman et al., 1994; Tang et al., 1994). However, in recent publications it was shown that D₃ receptors do activate G-proteins (Vanhauwe et al., 1999). However, it has not been established whether the slight modulation of agonist binding by guanine nucleotides is due to a particular interaction between the D₃ receptor and its target G-protein or that it is due to specific properties of the receptor itself. Our results confirm that GppNHp treatment does

not decrease the affinity of an agonist (^3H]7-OH-DPAT) for hD_3 receptors in CHO cell membranes. Most interestingly, we found that ^3H]7-OH-DPAT had similar affinities for hD_3 receptors in *E. coli* and CHO cell membranes (Table 1). This clearly shows that high affinity agonist binding to hD_3 receptor is almost independent of G-proteins, which makes it unlikely that a tight association between receptor and G-protein would prevent the effect of guanine nucleotides.

Inverse Agonists Do Not Have Higher Affinities for Uncoupled hD_2 and hD_3 Receptors. It was hypothesized that inverse agonists would have higher affinities for uncoupled than for coupled receptors (Costa et al., 1992). Antagonists tested in this study have been reported to be inverse agonists at hD_{2S} (haloperidol, domperidone, risperidone, spiperone, and nemonapride) and hD_3 receptors (haloperidol and raclopride) (Griffon et al., 1996; Hall and Strange, 1997; Kozell and Neve, 1997; Malmberg et al., 1998; Vanhauwe et al., 2000). However, Malmberg et al. (1998) reported no shift to higher affinities for inverse agonists at hD_3 receptors after pertussis toxin treatment of the membranes. Here, we demonstrate that in *E. coli* membranes, which are devoid of G-proteins, these presumed inverse agonists do not have higher affinities for hD_{2S} , hD_{2L} , or hD_3 receptors than in CHO cell membranes. Therefore, the theory of the allosteric ternary complex model with regard to inverse agonists seems not to be generally applicable.

A Purified Bovine G-Protein Mix Has a Comparable Affinity for hD_3 and hD_2 Receptors. It is not known why D_3 receptors activate G-proteins (much) less efficiently than D_2 receptors. Several hypotheses have been put forward, such as inability to activate and/or couple to G-proteins, unavailability of suitable G-proteins, or a low affinity toward G-proteins. To address this issue, we have tried to estimate the affinity of a subset of pertussis toxin-sensitive G-proteins for the hD_{2S} and hD_3 receptors. Therefore, we have reconstituted high affinity ^3H]7-OH-DPAT binding at hD_{2S}R - and hD_3R -*E. coli* membranes by addition of increasing concentrations of exogenous $\text{G}_{i/o}$ -proteins, purified from bovine brain. As was found before, no specific ^3H]7-OH-DPAT binding was detectable in the absence of G-proteins at hD_{2S}R -*E. coli* membranes, in contrast to hD_3R -*E. coli* membranes. However, the G-protein mix increased ^3H]7-OH-DPAT binding in a dose-dependent manner at either receptor, whereas it had no effect on antagonist binding (latter results not shown).

Most surprisingly, the G-protein mix was at least as potent in increasing high affinity agonist binding at hD_3 receptors than at hD_{2S} receptors. The estimated K_d of 1.4×10^{-7} M for the $\text{hD}_3\text{R}\cdot\text{G}_{i/o}$ complex and the K_d of 9.4×10^{-8} M for the $\text{hD}_{2S}\text{R}\cdot\text{G}_{i/o}$ complex corresponded to reported affinities of G-proteins for G-protein-coupled receptors. In addition, the G-protein/receptor ratio for half-maximal effect was similar to previous findings for A_1 -adenosine and 5HT_{1A} receptors in *E. coli* membranes (Bertin et al., 1992; Jockers et al., 1994) and slightly higher for dopamine D_{2S} receptors in Sf9 membranes (Grünewald et al., 1996). The G-protein/receptor ratio is probably overestimated due to the presence of inactive, purified G-protein contaminations and/or nonoptimal insertion of G-proteins in *E. coli* membranes. It cannot be concluded that more G-proteins per receptor were required for reconstituting high affinity binding at hD_3 receptors (versus hD_{2S} receptors), because more receptors were expressed in the hD_3 -*E. coli* membranes. Therefore, a more efficient way was

to calculate the K_d values based on our results (see Fig. 3 and legend), which showed that there was no difference in affinity between hD_{2S} and hD_3 receptors for the $\text{G}_{i/o}$ -protein mix. Until recently, it was generally believed that hD_3 receptors couple poorly to G-proteins when compared with D_2 receptors. Now, we found an equally strong interaction of hD_3 receptors compared with hD_2 receptors with a $\text{G}_{i/o}$ -protein mix. Robinson and Caron (1996) suggested a weak interaction between hD_3 receptors and G-proteins due to a constrained receptor structure. We propose a strong interaction between hD_3 receptors and G-proteins, but a rigid receptor structure that is little influenced by G-protein coupling. The rigid hD_3 receptor activates G-proteins less efficient than D_2 receptors. Hence, the receptor-G-protein interaction can be described by two independent parameters, analogous to the agonist-receptor interaction, i.e., affinity and intrinsic activity. In this respect, hD_3 receptors have a high affinity and a low intrinsic activity at G-proteins, whereas hD_2 receptors have a high affinity and a high intrinsic activity at G-proteins. In future studies, it will be interesting to define the different regions of the receptor that contribute to either G-protein coupling or activation.

In conclusion, we have expressed in *E. coli* hD_{2S} , hD_{2L} , and hD_3 receptors, which retained their antagonist binding properties. In *E. coli*, as well as in CHO cell membranes, agonist binding to uncoupled receptors was severely impaired at hD_{2S} and hD_{2L} receptors, whereas only a small effect was observed at hD_3 receptors. We found that the low and high affinity states of hD_3 receptors are similar, whereas for hD_{2S} and hD_{2L} receptors they are clearly distinguishable. Furthermore, our results indicate that hD_{2S} and hD_3 receptors have a similar affinity for an exogenously added $\text{G}_{i/o}$ -protein mix. Thus, the reported low signaling capacity of hD_3 receptors, as compared with hD_2 receptors, is not due to a low affinity for G-proteins but may be attributed to a constrained structure of the receptor.

Acknowledgments

We greatly appreciate the technical assistance of Monique Berben and the late Walter Gommeren.

References

- Akunne HC, Towers P, Ellis GJ, Dijkstra D, Wikström H, Heffner TG, Wise LD and Pugsley TA (1995) Characterization of binding of ^3H -PD128907, a selective dopamine D_3 receptor agonist ligand to CHO-K1 cells. *Life Sci* **57**:1401–1410.
- Bertin B, Freissmuth M, Breyer RM, Schutz W, Strosberg AD and Marullo S (1992) Functional expression of the human serotonin 5-HT_{1A} receptor in *Escherichia coli*. Ligand binding properties and interaction with recombinant G-protein alpha-subunits. *J Biol Chem* **267**:8200–8206.
- Cheng YC and Prusoff WH (1973) Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 per cent inhibition (IC_{50}) of an enzymatic reaction. *Proc Natl Acad Sci USA* **22**:3099–3108.
- Costa T, Ogino Y, Munson PJ, Onaran HO and Rodbard D (1992) Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: Thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. *Mol Pharmacol* **41**:549–560.
- Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR and McAllister G (1994) Expression and pharmacological characterization of the human dopamine D_3 receptor. *J Pharmacol Exp Ther* **268**:417–426.
- Freissmuth M, Selzer E, Marullo S, Schutz W and Strosberg AD (1991) Expression of two human β -adrenergic receptors in *Escherichia coli*: Functional interaction with two forms of the stimulatory G-protein. *Proc Natl Acad Sci USA* **88**:8548–8552.
- Giros B, Martres MP, Sokoloff P and Schwartz JC (1990) Gene cloning of human dopaminergic D_3 receptor and identification of its chromosome. *C R Acad Sci III* **311**:501–508.
- Griffon N, Pilon C, Sautel F, Schwartz JC and Sokoloff P (1996) Antipsychotics with inverse agonist activity at the dopamine D_3 receptor. *J Neural Transm* **103**:1163–1175.
- Grishammer R, Duckworth R and Henderson R (1993) Expression of a rat neurotensin receptor in *Escherichia coli*. *Biochem J* **295**:571–576.

- Grünewald S, Reiländer H and Michel H (1996) *In vivo* reconstitution of dopamine D_{2S} receptor-mediated G protein activation in baculovirus-infected insect cells: Preferred coupling to Gi1 versus Gi2. *Biochemistry* **35**:15162–15173.
- Hall DA and Strange PG (1997) Evidence that antipsychotic drugs are inverse agonists at D₂ dopamine receptors. *Br J Pharmacol* **121**:731–736.
- Jockers R, Linder ME, Hohenegger M, Nonoff C, Bertin B, Strosberg AD, Marullo S and Freissmuth M (1994) Species difference in the G-protein selectivity of the human and bovine A₁-adenosine receptor. *J Biol Chem* **269**:32077–32084.
- Kozell LB and Neve KA (1997) Constitutive activity of a chimeric D₂/D₁ dopamine receptor. *Mol Pharmacol* **52**:1137–1149.
- Lefkowitz RJ, Cotecchia S, Samama P and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. *Trends Pharmacol Sci* **14**:303–307.
- Leysen JE, Gommeren W, Mertens J, Luyten WH, Pauwels PJ, Ewert M and Seeburg P (1993) Comparison of *in vitro* binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D_{2S} and D_{2L} receptors and for D₂ receptors in rat striatal and mesolimbic tissues, using [¹²⁵I]2'-iodospiperone. *Psychopharmacology* **110**:27–36.
- Liu YF, Civelli O, Grandy DK and Albert PR (1992) Differential sensitivity of the short and the long human D₂ receptor subtypes to protein kinase C. *J Neurochem* **59**:2311–2317.
- MacKenzie RG, VanLeeuwen D, Pugsley TA, Shih Y-H, Demattos S, Tang L, Todd RD and O'Malley KL (1994) Characterization of the human dopamine D₃ receptor expressed in transfected cell lines. *Eur J Pharmacol* **266**:79–85.
- Malmberg A, Mikaelis A and Mohell N (1998) Agonist and inverse agonist activity at the dopamine D₃ receptor measured by guanosine 5'-[γ-thio]triphosphate-[³⁵S] binding. *J Pharmacol Exp Ther* **285**:119–126.
- Marullo S, Emorine LJ, Strosberg AD and Delavie-Klutchko C (1990) Selective binding of ligands to β₁, β₂ or chimeric β₁/β₂-adrenergic receptors involves multiple subsites. *EMBO J* **9**:1471–1476.
- McAllister G, Knowles MR, Ward-Booth SM, Sinclair HA, Patel S, Marwood R, Emms F, Smith A, Seabrook GR and Freedman SB (1995) Functional coupling of human D₂, D₃ and D₄ dopamine receptors in HEK293 cells. *J Recept Signal Transduct Res* **15**:267–281.
- Missale C, Nash SR, Robinson SW, Jaber M and Caron MG (1998) Dopamine receptors: From structure to function. *Physiol Rev* **78**:189–225.
- Monsma FJ, McVittie LD, Gerfen CR, Mahan LC and Sibley DR (1989) Multiple D₂ dopamine receptors produced by alternative RNA splicing. *Nature (Lond)* **342**:926–929.
- Munch G, Walker P, Shine J and Herzog H (1995) Ligand binding analysis of human neuropeptide Y1 receptor mutants expressed in *E. coli*. *Receptors Channels* **3**:291–297.
- Oestreicher EG and Pinto GF (1987) A microcomputer program for fitting enzyme inhibition equations. *Comput Biol Med* **17**:53–68.
- Palermo DP, De Graaf ME, Marotti KR, Rehberg E and Post LE (1991) Production of analytical quantities of recombinant proteins in Chinese hamster ovary cells using sodium butyrate to elevate gene expression. *J Biotechnol* **19**:35–47.
- Picetti R, Saiardi A, Abdel Samad T, Bozzi Y, Baik JH and Borrelli E (1997) Dopamine D₂ receptors in signal transduction and behavior. *Crit Rev Neurobiol* **11**:141–142.
- Robinson SW and Caron NG (1996) Chimeric D₂/D₃ dopamine receptors efficiently inhibit adenylyl cyclase in HEK 293 cells. *J Neurochem* **67**:212–219.
- Samama P, Cotecchia S, Costa T and Lefkowitz RJ (1993) A mutation-induced activated state of the beta-2 adrenergic receptor. Extending the ternary complex model. *J Biol Chem* **268**:4625–4636.
- Sander P, Grünewald S, Maul G, Reiländer H and Michel H (1994) Constitutive expression of the human D_{2S}-dopamine receptor in the unicellular yeast *Saccharomyces cerevisiae*. *Biochim Biophys Acta* **1193**:255–262.
- Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage A, De Loore K and Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: *In vitro* and *in vivo* receptor binding. *Psychopharmacology* **124**:57–73.
- Sokoloff P, Andrieux M, Besançon R, Pilon C, Martres M-P, Giros B and Schwartz J-C (1992) Pharmacology of human dopamine D₃ receptor expressed in a mammalian cell line: Comparison with D₂ receptor. *Eur J Pharmacol* **225**:331–337.
- Tang L, Todd RD, Heller A and O'Malley KL (1994) Pharmacological and functional characterization of D₂, D₃ and D₄ dopamine receptors in fibroblast and dopaminergic cell lines. *J Pharmacol Exp Ther* **268**:495–502.
- Vanhauwe JFM, Ercken M, Van de Wiel D, Jurzak M and Leysen JE (2000) Effects of recent and reference antipsychotic agents at human dopamine D₂ and D₃ receptor signaling in Chinese hamster ovary cells. *Psychopharmacology* **150**:383–390.
- Vanhauwe JFM, Fraeyman N, Francken BJB, Luyten WHML and Leysen JE (1999) Comparison of the ligand binding and signaling properties of human dopamine D₂ and D₃ receptors in Chinese Hamster Ovary cells. *J Pharmacol Exp Ther* **290**:908–916.

Send reprint requests to: Josée E. Leysen, Janssen Pharmaceutica, Turnhoutseweg 30, B-2340 Beerse, Belgium. E-mail: jleysen2@janbe.jnj.com
